Gene
HOXD8
homeobox D8
Explore in graph →CI-GENE-00004968HGNC:5139 ENSG00000175879 NCBI 3234 CIViC Approved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24265153
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HOXD8 mutation1 | ||||||||
| Dabrafenib + VemurafenibSubstitutes | Melanoma | Predictive | C | Supports Resistance | 2 | submitted | EID7670In a retrospective study, resistance mechanisms to BRAF inhibitor such as vemurafenib or dabrafenib in patients with BRAF V600 mutated melanoma were evaluated. A nonsense mutation in the HOXD8 gene wa… (full text at CIViC) PMID 24265153 · Van Allen et al., 2014 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (0)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
Data not yet available
No cohort frequency recorded for this gene.
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.